DigestRedComo funciona
Red
/
Empresas
Ma
No verificado

Marea Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaCardiologíaFarmacéuticaMedicina - VariosSalud

12 Comunicados de prensa

Ver todos los comunicados de prensa
12/08/2025
Ciencia
Biotecnología
Medicina - Varios
Cardiología
Farmacéutica
Ir de compras
Salud
Industria
Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly
Fuente
Marea Therapeutics, Inc.
Editor
Business Wire
1.00
0
04/08/2025
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Cardiología
Industria
Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD
Fuente
Marea Therapeutics, Inc.
Editor
Business Wire
1.00
0
14/07/2025
Ciencia
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Eventos
Industria
Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025
Fuente
Marea Therapeutics, Inc.
Editor
Business Wire
1.00
0
01/07/2025
Ciencia
Biotecnología
Medicina - Varios
Cardiología
Biología
Sanidad
Farmacéutica
Salud
Mercado laboral
Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer
Fuente
Marea Therapeutics, Inc.
Editor
Business Wire
1.00
0
24/06/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Ferias y Congresos
Eventos
Industria
Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025
Fuente
Marea Therapeutics, Inc.
Editor
Business Wire
1.00
0
20/05/2025
Mercado laboral
Biotecnología
Salud
Farmacéutica
Cardiología
Marea Therapeutics Appoints Charmi Turner as Senior Vice President, People & Culture
Fuente
Marea Therapeutics, Inc.
Editor
Business Wire
1.00
0
16/05/2025
Industria
Biotecnología
Salud
Medicina - Varios
Cardiología
Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
Fuente
Marea Therapeutics, Inc.
Editor
Business Wire
1.00
0
07/05/2025
Eventos
Industria
Análisis de Mercados
Cardiología
Biotecnología
Higiene alimentaria
Sanidad
Salud
Farmacéutica
Ciencia
Medicina - Varios
Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
Fuente
Marea Therapeutics, Inc.
Editor
Business Wire
1.00
0
15/04/2025
Eventos
Ciencia
Biotecnología
Medicina - Varios
Cardiología
Sanidad
Salud
Farmacéutica
Marea Therapeutics Announces Late-Breaking Oral Presentation at the 93rd EAS Congress
Fuente
Marea Therapeutics, Inc.
Editor
Business Wire
1.00
0
21/01/2025
Mercado laboral
Ciencia
Salud
Medicina - Varios
Cardiología
Biotecnología
Farmacéutica
Marea Therapeutics Forms Clinical Scientific Advisory Board
Fuente
Marea Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0